# Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis

> **NCT05532943** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ever Supreme Bio Technology Co., Ltd.** · enrollment: 41 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Allogeneic umbilical cord mesenchymal stem cells
- **BIOLOGICAL:** Control group

## Key facts

- **NCT ID:** NCT05532943
- **Lead sponsor:** Ever Supreme Bio Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-08
- **Primary completion:** 2028-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05532943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05532943, "Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05532943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*